CMV Vaccines: Reinfection and Antigenic Variation (Vision and auditory screening in infants born to women enrolled in ZIP)

CMV 疫苗：再感染和抗原变异（参加 ZIP 的妇女所生婴儿的视力和听觉筛查）

• 批准号: 9472616
• 负责人: William Jarvis Britt
• 金额: $ 3.27万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-05-01 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9472616
• 关键词: Adult; Antibodies; Antibody Response; Antigenic Variation; Auditory; Characteristics; Child; Child health care; Complex; Controlled Study; Cytomegalovirus; Cytomegalovirus Infections; Cytomegalovirus Vaccines; Development; Disease; Enrollment; Exhibits; Exposure to; Female of child bearing age; Fetus; Genotype; Goals; Herd Immunity; Human; Human Characteristics; Immune; Immune response; Immunity; Immunologics; Incidence; Individual; Infant; Infection; Infection prevention; Intervention; Lead; Live Birth; Minor; Morbidity - disease rate; Mothers; Natural History; Neurodevelopmental Disorder; Neurologic; Northern Europe; Population; Pregnancy; Preventive Intervention; Preventive vaccine; Recurrence; Risk; Role; Secondary to; Seroprevalences; Source; Testing; Therapeutic Intervention; Transplant Recipients; Urban Population; Vaccines; Viral; Viral Antibodies; Virus; Virus Diseases; Vision; Woman; base; burden of illness; congenital infection; design; fetal infection; genome-wide; hearing impairment; in utero; offspring; prophylactic; screening; therapeutic vaccine; transmission process; viral transmission; virology

DESCRIPTION (provided by applicant): Human cytomegalovirus (HCMV) infection represents the most common viral infection transmitted in-utero and is a significant cause of neurodevelopmental disorders in children. The rate of congenital HCMV infection ranges from 0.2-1.0% of live births in the US and exceeds 1% in many parts of the world. Although maternal infection during pregnancy (primary maternal infection) represents a significant risk for virus transmission to the fetus and disease, infection and transmission to the fetus in women with existing immunity to this virus (non-primary maternal infection) is frequent. Disease in babies infected following non-primary maternal infection is well documented. Worldwide, including most US populations, the disease burden in infected infants born to women with non-primary infections exceeds that of offspring of women with primary maternal infection. In this proposal we will explore two mechanisms of non-primary maternal infections, reinfection with new strain of viruses and recurrence/reactivation of a persistent infection. Our goals are to define virological characteristics of non-primary infections and parameters of HCMV specific immunity in a highly seroimmune population in which non-primary maternal infections account for the vast majority of infected babies. We will also determine the incidence of the most common long term sequelae of congenital HCMV infection, hearing loss, in infected babies. We anticipate these studies will help identify host responses associated with intrauterine transmission and damaging fetal infections in this population of women with non-primary infection and could aid in the rationale development of effective prophylactic and possibly therapeutic vaccines to limit the morbidity from this congenital infection.

描述（由申请人提供）：人类巨细胞病毒（HCMV）感染代表了UTERO中传播的最常见的病毒感染，是儿童神经发育障碍的重要原因。先天性HCMV感染的发生率在美国许多地区的活产范围为0.2-1.0％，超过1％。尽管怀孕期间的孕产妇感染（原发性母亲感染）代表了病毒向胎儿和疾病传播的重大风险，但经常出现对这种病毒免疫（非主要母亲感染）的妇女的感染和向胎儿传播。在非主要母体感染后感染的婴儿中的疾病已充分记录。全世界，包括大多数美国人口，非主要感染妇女出生的受感染婴儿的疾病负担超过了原发性孕产妇感染的妇女的后代。在此提案中，我们将探讨两种非主要母体感染的机制，并通过新的病毒菌株再感染以及持续感染的复发/重新激活。我们的目标是定义非主要感染的病毒学特征和HCMV特异性免疫的参数，在高度血清免疫种群中，非主要母体感染占绝大多数感染婴儿。我们还将确定感染婴儿中先天性HCMV感染，听力损失的最常见的长期后遗症的发生率。我们预计这些研究将有助于确定与非主要感染的妇女人群中与宫内传播和损坏胎儿感染有关的宿主反应，并可能有助于开发有效的预防性和可能的​​治疗疫苗，以限制这种先天性感染的发病率。